Inferior Vena Cava (IVC) Filters Market Size, Share, Industry, Forecast and outlook (2024-2031)

Inferior Vena Cava (IVC) Filters Market is Segmented By Types (Retrievable, Permanent), By Application (Treatment of Venous Thromboembolism, Prevention of Pulmonary Embolism), By End User (Hospitals, Ambulatory Surgical Centers, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Inferior Vena Cava (IVC) Filters Market Overview

The Global Inferior Vena Cava (IVC) Filters Market is expected to reach at a CAGR of 8.5% during the forecast period (2023-2030). Inferior vena cava filters are mechanical devices implanted in the inferior vena cava by vascular surgeons or interventional radiologists to prevent potentially fatal pulmonary emboli. The blood clots are trapped in the filter until the body dissolves them. The IVCF procedure is usually quick and painless.

Inferior Vena Cava (IVC) Filters Market Summary and Scope

Inferior Vena Cava (IVC) Filters Market Dynamics and Trends

The number of people diagnosed with cardiovascular diseases and the rising demand for optional and retrievable IVC filters has resulted in market growth for inferior vena cava filters. Furthermore, increasing innovation in patient retrieval approaches is more likely to drive market growth. The development of digital catheterization laboratories is expected to provide opportunities for market expansion. Furthermore, rising public awareness of inferior vena cava filter treatments and government initiatives and investments to establish advanced infrastructure facilities are expected to drive market growth in the inferior vena cava market during the forecast period.

The increase in prevalance of venous thromboembolism in the market will drive the market growth

The rising prevalence of cardiac ailments and the growing demand for minimally invasive techniques are driving the market growth. IVCF is prescribed for patients who have had an acute venous thromboembolic event (VTE) but cannot receive anticoagulation. IVCF is also frequently recommended for patients who are thought to have failed anticoagulation.

Inferior vena cava filters (IVCF) were designed to prevent pulmonary embolism (PE) and reduce venous thromboembolism (VTE)-related mortality. VTE is becoming more common all over the world. According to the Centers for Disease Control and Prevention (CDC), while the exact number of people affected by VTE is unknown, as many as 900,000 people (1 to 2 per 1,000) may be affected each year in the United States. Because of this rising prevalence, the inferior vena cava filters market is expected to expand rapidly. This contributes to the growth of the global inferior vena cava (IVC) filters market.

High cost of  procedures is likely to hamper the market growth

The treatment of inferior vena cava involves more expensive procedures, which impedes the market growth. The lack of awareness about IVC treatment among people in rural areas in emerging countries is viewed as a barrier to the growth of the inferior vena cava filter market.

COVID-19 Impact Analysis on Inferior Vena Cava (IVC) Filters Market

The COVID-19 outbreak has impacted the inferior vena cava market in 2020. According to a National Library of Medicine report, venous registry volumes were cut in half in the first quarter of 2020 compared to the same period in 2019. The consequences of postponing vascular procedures for ambulatory venous practice are unknown, but increased morbidity is possible. Given the difficulty in verifying "in-home and extended care facility" deaths, determining the impact of venous thromboembolism mortality is difficult. The consequences of a pandemic shutdown will most likely be exacerbated if elective vascular care is postponed for an extended period. Furthermore, according to a study published in Vascular and Interventional Radiology, PE response team (PERT) calls decreased significantly during the period. Due to a severe shortage of required personnel, there was an influx of physicians caring for COVID-19 patients who were not used to managing intensive care unit (ICU)-level patients.

Inferior Vena Cava (IVC) Filters Market Segmentation Analysis

The retrievable IVCF segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)     

Retrievable vena cava filters are finding new prophylactic applications in new patient populations at risk for venous thromboembolism. Bariatric, orthopedic, trauma, neurosurgical, and cancer patients may be at risk. They are also increasingly being used by physicians who are afraid of being sued. Furthermore, as retrievable IVC filter designs improve, making them easier to deploy and remove, and their perceived increased risk of fracture, embolization, and IVC wall penetration decreases, their benefits will continue to outweigh their risks, and their use will increase. The long-term risks of permanent filter placement, retrievable IVC filters have gradually become a more appealing option. These devices are technically feasible for percutaneous insertion and retrieval while providing PE protection.

The advancement of advanced filter retrieval techniques has had a significant impact on the removal of embedded RIVCFs, allowing most devices to be retrieved. The development of advanced retrieval techniques has had a significant impact on retrieving a RIVCF that is embedded or has had an extended implantation time. A recent study found that RIVCFs can be successfully removed using advanced techniques regardless of dwell time.

Günther Tulip and Celect filters (Cook Medical), OptEase filter (Cordis Endovascular), and G2 and G2 Express filters are among the FDA-approved retrievable IVC filters (Bard Peripheral Vascular). demand in surgeries and transfusions, all of which are key drivers to the segment's growth.

Inferior Vena Cava (IVC) Filters Market Geographical Share

North America region holds the largest market share of Global Inferior Vena Cava (IVA) Filters Market

The Centers for Disease Control and Prevention and National Center on Birth Defects and Developmental Disabilities stated that venous thromboembolism kills 60,000-100,000 Americans each year. It is expected that 10 to 30% of people will die within one month of being diagnosed. In about one-quarter (25 percent) of people with PE, the first symptom is sudden death. Long-term complications (post-thrombotic syndrome) such as swelling, pain, discoloration, and scaling in the affected limb are common in people who have had a VTE. One-third (approximately 33 percent) of VTE patients are expected to recurrence within 10 years.

Around 5 to 8% of the U.S. population has several genetic risk factors, also known as inherited thrombophilias. A genetic defect that increases the risk of thrombosis can be identified. This high prevalence of diseases is expected to drive the market growth throughout the region.

Inferior Vena Cava (IVC) Filters Companies and Competitive Landscape

The inferior vena cava filters market is highly competitive with presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include C.R. Bard, Boston Scientific , Cardinal Health, Cook Medical , B.Braun, ALN, Braile Biomedica, Philips Volcano, Argon Medical Devices, VENITI.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the blood and blood products market globally. For instance The first laser-based device to remove Inferior Vena Cava (IVC) filters was approved for marketing by the US Food and Drug Administration on December 21, 2021. The device is intended for patients who have an IVC filter, a small cage-like device inserted into the body's largest vein to capture blood clots and prevent them from traveling to the lungs. The Philips CavaClear Laser Sheath is a new device designed to remove tissue to facilitate the detachment of an IVC filter during retrieval when previous removal methods have failed.

Argon Medical Devices

Overview: Argon Medical, headquartered in Frisco, Texas, is a global manufacturer of specialty medical products. Argon Medical Devices provides a diverse range of medical devices for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology. The Argon brand produces best-in-class products that improve patient outcomes through percutaneous, image-guided procedures. Argon serves its global customers through a direct sales organization and long-standing relationships with medical device distributors, strategic partners, and OEMs, leveraging a well-establishedsales and marketing infrastructure.

Product Portfolio:

Triple-Loop Retrieval Kits:  An outer sheath is reinforced with strong coils to detach filter legs from the IVC wall. Radiopaque bands on the distal ends of the inner sheath, outer sheath, and snare catheter for improved visibility.The distal tip of the snare catheter has a fifteen-degree curve for directional control.